July 7, 2023 - The US Health Care ETF market experienced a decline of -1.48% in its performance yesterday, as investors expressed concerns over the sector's prospects. This market, valued at approximately 5 billion euros and consisting of 10 exchange-traded funds (ETFs), witnessed a widespread negative trend. Several prominent ETFs, including the First Trust NYSE Arca Biotechnology UCITS ETF (FBTU), iShares Nasdaq US Biotechnology UCITS ETF (XLON:BTEC), iShares US Medical Devices UCITS ETF (UMDV), and Xtrackers MSCI USA Health Care UCITS ETF (XUHC), recorded daily returns of -0.82%, -0.84%, -0.30%, and -1.13%, respectively.

Driving this downturn were influential healthcare companies, with shares of Merck & Co, Lilly, Gilead Sciences, and Vertex Pharmaceuticals all suffering considerable setbacks. Merck & Co, a leading healthcare firm, experienced a -2.46% daily return and a -5.54% decline over the span of one week. Similarly, Lilly observed a -2.40% daily return and a -3.60% decline over one week. Gilead Sciences and Vertex Pharmaceuticals also faced declines of -2.39% and -2.19% in their daily returns, respectively, alongside -3.44% and -3.90% declines in their one-week performance. The market's movement appears to indicate investor uncertainty regarding the ongoing dynamics within the health care sector and the future prospects of these companies.

See how over 500 professional investors use ETFs in the 2023 Trackinsight Global ETF Survey. Get access today.